home / stock / snynf / snynf quote
Last: | $100 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $100 |
High: | $0 |
Low: | $0 |
Volume: | 2,845 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$100 | $0 | $100 | $0 | $0 | 2,845 | 05-02-2024 |
$100 | $97.76 | $100 | $100 | $96.64 | 535 | 05-01-2024 |
$95.544 | $0 | $95.544 | $0 | $0 | 33 | 04-30-2024 |
$95.544 | $0 | $95.544 | $0 | $0 | 228 | 04-29-2024 |
$95.544 | $0 | $95.544 | $0 | $0 | 28 | 04-26-2024 |
$95.544 | $95.544 | $95.544 | $95.544 | $95.544 | 299 | 04-25-2024 |
$94 | $95 | $94 | $95 | $94 | 310 | 04-24-2024 |
$94.25 | $94.25 | $94.25 | $94.25 | $94.25 | 482 | 04-23-2024 |
$92.7 | $0 | $92.7 | $0 | $0 | 77 | 04-22-2024 |
$92.7 | $0 | $92.7 | $0 | $0 | 84 | 04-19-2024 |
$92.7 | $92.7 | $92.7 | $92.7 | $92.7 | 600,729 | 04-18-2024 |
$92.7 | $92.23 | $92.7 | $92.7 | $91.48 | 1,429 | 04-17-2024 |
$92.116 | $91.336 | $92.116 | $92.116 | $91.336 | 2,296 | 04-16-2024 |
$92.966 | $92.406 | $92.966 | $92.966 | $92.406 | 633 | 04-15-2024 |
$92.9 | $0 | $92.9 | $0 | $0 | 66,090 | 04-12-2024 |
$92.9 | $93.4 | $92.9 | $93.4 | $92.9 | 884 | 04-11-2024 |
$94.25 | $94.25 | $94.25 | $94.25 | $94.25 | 1,295 | 04-10-2024 |
$94.26 | $94.26 | $94.26 | $94.26 | $94.26 | 693 | 04-09-2024 |
$94 | $94.762 | $94 | $94.762 | $94 | 1,566 | 04-08-2024 |
$92.69 | $94.4 | $92.69 | $94.4 | $92.69 | 239 | 04-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus n...
Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023 Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024 Board composition: renewal of two Directors and appointment of three new Independent Di...
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS (1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€...